|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAST |
Gene summary for GAST |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAST | Gene ID | 2520 |
| Gene name | gastrin | |
| Gene Alias | GAS | |
| Cytomap | 17q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A0E3VY36 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2520 | GAST | C04 | Human | Oral cavity | OSCC | 4.95e-17 | 8.55e-01 | 0.2633 |
| 2520 | GAST | C21 | Human | Oral cavity | OSCC | 2.81e-08 | 3.15e-01 | 0.2678 |
| 2520 | GAST | C30 | Human | Oral cavity | OSCC | 1.26e-09 | 7.12e-01 | 0.3055 |
| 2520 | GAST | C57 | Human | Oral cavity | OSCC | 3.06e-02 | 1.28e-01 | 0.1679 |
| 2520 | GAST | SYSMH3 | Human | Oral cavity | OSCC | 6.89e-14 | 9.40e-01 | 0.2442 |
| 2520 | GAST | Pat04-B | Human | Stomach | GC | 2.32e-02 | 1.09e-01 | -0.1483 |
| 2520 | GAST | Pat05-B | Human | Stomach | GC | 8.26e-19 | 4.77e-01 | -0.0353 |
| 2520 | GAST | Pat12-B | Human | Stomach | GC | 8.43e-08 | 3.54e-01 | 0.0325 |
| 2520 | GAST | Pat18-B | Human | Stomach | GC | 9.44e-14 | 3.60e-01 | -0.0432 |
| 2520 | GAST | Pat22-B | Human | Stomach | GC | 4.55e-06 | 1.37e-01 | -0.1042 |
| 2520 | GAST | Pat25-A | Human | Stomach | CAG with IM | 2.85e-23 | 3.88e-01 | -0.1648 |
| 2520 | GAST | Pat26-A | Human | Stomach | CSG | 2.14e-76 | 1.02e+00 | -0.2402 |
| 2520 | GAST | NAG_1 | Human | Stomach | CSG | 4.12e-65 | 1.41e+00 | -0.3534 |
| 2520 | GAST | NAG_2 | Human | Stomach | CSG | 5.99e-77 | 1.55e+00 | -0.3324 |
| 2520 | GAST | NAG_3 | Human | Stomach | CSG | 1.17e-74 | 1.72e+00 | -0.2816 |
| 2520 | GAST | CAG_1 | Human | Stomach | CAG | 6.42e-47 | 1.68e+00 | -0.3206 |
| 2520 | GAST | CAG_2 | Human | Stomach | CAG | 2.32e-146 | 2.09e+00 | -0.2831 |
| 2520 | GAST | CAG_3 | Human | Stomach | CAG | 5.25e-158 | 2.31e+00 | -0.2766 |
| 2520 | GAST | WIM_1 | Human | Stomach | WIM | 4.66e-08 | 3.89e-01 | 0.0335 |
| 2520 | GAST | WIM_2 | Human | Stomach | WIM | 1.76e-24 | 8.04e-01 | 0.1159 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
| GO:00316676 | Stomach | GC | response to nutrient levels | 56/1159 | 474/18723 | 2.47e-06 | 1.06e-04 | 56 |
| GO:003166711 | Stomach | CAG with IM | response to nutrient levels | 48/1050 | 474/18723 | 5.51e-05 | 1.38e-03 | 48 |
| GO:003166721 | Stomach | CSG | response to nutrient levels | 49/1034 | 474/18723 | 1.83e-05 | 5.57e-04 | 49 |
| GO:003166731 | Stomach | CAG | response to nutrient levels | 32/552 | 474/18723 | 1.28e-05 | 5.12e-04 | 32 |
| GO:00316674 | Stomach | WIM | response to nutrient levels | 31/426 | 474/18723 | 1.54e-07 | 1.46e-05 | 31 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAST | SNV | Missense_Mutation | novel | c.23N>C | p.Val8Ala | p.V8A | P01350 | protein_coding | tolerated_low_confidence(0.54) | benign(0.001) | TCGA-E9-A3Q9-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphane | CR |
| GAST | insertion | Frame_Shift_Ins | novel | c.283_284insCT | p.Arg95ProfsTer? | p.R95Pfs*? | P01350 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAST | insertion | Nonsense_Mutation | novel | c.284_285insTCTCAATAAATAAATAAATTACATTATTTAAACAGCTA | p.Ser96LeufsTer4 | p.S96Lfs*4 | P01350 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAST | SNV | Missense_Mutation | c.65N>G | p.Ser22Cys | p.S22C | P01350 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GAST | SNV | Missense_Mutation | c.115N>G | p.Asn39Asp | p.N39D | P01350 | protein_coding | tolerated_low_confidence(0.08) | benign(0.346) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD | |
| GAST | SNV | Missense_Mutation | c.47N>T | p.Ala16Val | p.A16V | P01350 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.851) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GAST | SNV | Missense_Mutation | c.300G>T | p.Glu100Asp | p.E100D | P01350 | protein_coding | tolerated_low_confidence(0.57) | benign(0.079) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GAST | SNV | Missense_Mutation | novel | c.297T>G | p.Asp99Glu | p.D99E | P01350 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| GAST | SNV | Missense_Mutation | c.283N>T | p.Arg95Cys | p.R95C | P01350 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.982) | TCGA-DD-A3A5-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| GAST | SNV | Missense_Mutation | novel | c.23N>C | p.Val8Ala | p.V8A | P01350 | protein_coding | tolerated_low_confidence(0.54) | benign(0.001) | TCGA-DD-AACQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2520 | GAST | DRUGGABLE GENOME, HORMONE ACTIVITY, ENZYME | G17DT | |||
| 2520 | GAST | DRUGGABLE GENOME, HORMONE ACTIVITY, ENZYME | G17DT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |